Last edition
News about "GLP-1 receptor "
India’s drug regulator Central Drugs Standard Control Organisation warns pharmaceutical firms against direct or indirect promotion of prescription-only GLP-1 drugs for obesity, stressing strict compliance with the Drugs and Cosmetics Act, 1940.
GLP-1 Receptor | 13/03/2026 | By News Bureau
Ascletis Receives FDA IND Clearance for Phase II ASC30 Diabetes Study
Ascletis has received US FDA IND clearance to initiate a 13-week phase-II, randomised, double-blind, placebo-controlled, multi-centre study evaluating the efficacy, safety and tolerability of its oral small-molecule GLP-1 candidate ASC30 in participants with diabetes, with enrollment expected to begin in the first quarter of 2026.
GLP-1 Receptor | 05/01/2026 | By News Bureau | 127
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy